Stocks / Dr Reddy's Laboratories (DRREDDY)

DRREDDY Share Price, Analysis & News

Dr Reddy's Laboratories (DRREDDY) — Updated on 2026-06-22

Dr. Reddy's Laboratories Limited is an India-based pharmaceutical company operating within the biotechnology & drugs sector. The company's business model focuses on its operations as a pharmaceutical entity. Investors closely monitor the Dr Reddy's Laboratories share price to understand its market performance and potential. Analysis of Dr Reddy's Laboratories business model involves examining its core pharmaceutical activities and how they align with broader trends in the biotechnology and drug industry. Understanding the company's fundamentals and earnings reports provides insight into its financial health and its position within the competitive landscape of the pharmaceutical market.
Overview Daily Weekly

Key Takeaway

Dr Reddy's shows a bullish technical trend but faces headwinds from sharp revenue and profit declines, alongside an elevated P/E ratio.

Daily

2026-06-22
  • The stock shows a bullish trend alignment, trading above its 50-day and 200-day moving averages, with positive short-term returns of 1.42% in the last day. However, momentum indicators are mixed, with a neutral RSI of 52.83 and a bearish MACD signal, suggesting caution despite the upward price action.
  • Despite a bullish technical trend, the company's recent financial performance has significantly deteriorated. Revenue decreased by 11.515% year-over-year to ₹7,546 Cr in March 2026, and net profit saw a sharp decline of 86.074% year-over-year to ₹221 Cr, indicating substantial challenges.
  • The company's valuation appears elevated, with the current P/E multiple at 33.5x, which is 36.452% higher than its 6-month average. This suggests that the market is pricing in future growth despite the recent poor financial results.
  • Analyst sentiment remains divided, with a notable 28.95% of ratings falling into Sell or Strong Sell categories, even though 47.37% are Strong Buy or Buy. This divergence in opinion highlights uncertainty about the company's future prospects.
  • Institutional investors continue to hold a significant stake (51.86%), led by DIIs at 30.72%. However, a 1.2% decrease in FII holdings QoQ, coupled with an increase in public holdings, suggests a potential shift in foreign investor confidence.
  • Recent company announcements include newspaper publications under Regulation 30 (LODR) on June 20, 2026, and an allotment of ESOP/ESPS on June 19, 2026. While these are routine events, they indicate ongoing corporate activity.
Open daily analysis

Weekly

Latest weekly signal
  • The stock declined by 0.19% this week, influenced by a downward price trend and reduced trading volume.
  • Dr. Reddy's launched the first generic version of Bosulif (Bosutinib Tablets 400mg) in the U.S., securing 180 days of market exclusivity.
  • Technical indicators show mixed signals, with a neutral Relative Strength Index (RSI) at 45.7 and a slight downward bias in the 10-week price trend.
  • The company reported a significant decrease in performance for the quarter ending March 2026, with revenue down 11.5% and net profit down 86.1% year-over-year.
  • Average daily trading volume decreased by 28.79% compared to the previous week, indicating lower investor participation.
Open weekly analysis

Quarterly

Latest quarterly update
Detailed analysis available on the full page.

Price & Technical Structure

  • The stock has shown positive short-term returns, with a 1.42% gain in the last day and 0.84% over the last 5 days, despite a negative 1-month return of -2.15%.
  • The trend alignment score is 3, indicating a bullish trend, with the price trading above the 50-day and 200-day moving averages.
  • Momentum indicators suggest a neutral stance, with an RSI of 52.83 and a bearish MACD signal.
  • Volatility remains moderate, with the price positioned at 60.02% of the Bollinger Band width and an annualized volatility of 12.62%.
  • The stock is trading 4.63% below its 52-week high and 11.64% above its 52-week low, with a current drawdown of -4.63%. The delivery trend shows accumulation.
The stock exhibits a bullish trend alignment with prices trading above key moving averages. However, momentum is neutral to bearish, as indicated by the RSI and MACD. Volatility is moderate, and the stock is positioned within its 52-week range, showing signs of accumulation in delivery volumes. The short-term returns are positive, though the 1-month return is negative.

Weekly Momentum

  • The stock declined by 0.19% this week, influenced by a downward price trend and reduced trading volume.
  • Dr. Reddy's launched the first generic version of Bosulif (Bosutinib Tablets 400mg) in the U.S., securing 180 days of market exclusivity.
  • Technical indicators show mixed signals, with a neutral Relative Strength Index (RSI) at 45.7 and a slight downward bias in the 10-week price trend.
  • The company reported a significant decrease in performance for the quarter ending March 2026, with revenue down 11.5% and net profit down 86.1% year-over-year.
  • Average daily trading volume decreased by 28.79% compared to the previous week, indicating lower investor participation.
Dr. Reddy's Laboratories experienced a mixed week. While the company announced a significant product launch in the U.S. with associated market exclusivity, the stock price saw a slight decline. This was accompanied by reduced trading volume and mixed technical signals, including a neutral RSI and a downward price trend over the last 10 weeks. The recent quarterly results ending March 2026 showed a substantial drop in revenue and net profit, which may be weighing on investor sentiment despite the positive news from the U.S. market.

The company's valuation remains elevated with a PE ratio of 33.0x and a PB ratio of 3.4x, while the technical picture suggests a neutral to slightly bearish short-term outlook due to the divergence between short-term and long-term moving averages and weak momentum.